Protect the Department of Defense CDMRP Prostate Cancer Research Program (DoD PCRP)

YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]

Update on Potential DOD Funding for the Prostate Cancer Program

From Anthony Hardie, Madison, Wis. All: I've just gone through the full Defense Committee bill (before yesterday's markup) and the corresponding report language on the various CDMRP programs. The results are below. FY12 Defense Appropriations -- Full Committee Bill (before yesterday's markup): 1. Several programs would not be funded at all: most notably the sort [...]

A Personal Request – Help Us Save The Prostate Cancer Research Program at the Department of Defense

U.S. SENATE: Save the Prostate Cancer Research Program Now it is time to write your U.S. Senators - TODAY! A few weeks ago I requested that you write to your member of the House of Representatives, now it is time to write to the other side of congress, the Senate. Write your U.S. Senators today [...]

A Personal Request – Help Us Save The Prostate Cancer Research Program at the Department of Defense

Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved [...]

FDA Approves Zytiga (abiraterone acetate) for Late-Stage Prostate Cancer

The long awaited FDA approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy has happened! Malecare celebrates this approval as it celebrates the significant numbers of new drug approvals we have had over the last year and one half. The approval of Zytiga represents [...]

Go to Top